Phone
+33 (0)1 76 54 08 64

Email
contact@proimaging.fr

Address
66 avenue des Champs-Élysées
75008 Paris – France

WMIC 2018 – CJ215, a new ultrasensitive near-infrared fluorescent probe for enhanced tumor detection in vivo: a comparative study with ICG in a preclinical model

Authors: Valérie Rouffiac, Corinne Laplace-Builhé, Michel Urbain, Mélanie Polrot, François Scherninski

Abstract: The optimization of detection of subclinical lesions and intraoperative margins delineation is an important challenge in oncology to decrease the risk of local recurrence and preserve healthy tissue. For many years, clinical trials using near-infrared (NIR) optical imaging combined with ICG as contrast agent, try to address these issues. ICG is already approved for clinical use, but as a blood pool agent, it is not specific to tumor tissue. ICG shows a passive targeting based on enhanced permeability and retention effect, and thus is not ideally suited for image-guided surgery. In the present work, we assessed a new NIR fluorescent probe, the CJ215, in comparison with ICG, for tumor detection in a preclinical model of orthotopic mammary cancer.

Read more

Proimaging provided fluorescent labeling dyes LBL-Dye M715 and LBL-Dye M717 to the Primacen cell imaging research platform for…

Proimaging provided fluorescent labeling dyes to INRAE for a study on cervical sperm…

Proimaging provided 3 NIR coupling dyes to the Laboratory of Immunology – Cell Therapy and Hematopoiesis at CHU de Rennes…

Proimaging